Etanercept

Tsutomu Takeuchi, Koichi Amano

研究成果: Review article査読

1 被引用数 (Scopus)

抄録

Etanercept is a protein comprised of the extracellular domains of two TNF receptors attached to a Fc portion of an IgG. Etanercept was approved for not only reducing signs and symptoms but inhibiting of structural damage in patients with active RA who had an inadequate response to one or more DMARDs. Moreover, combination therapy with methotrexate will be attractive for severely active patients. The proportion of patients who have discontinued therapy due to adverse events is approximately 4%. Etanercept has not raised the risk for serious infections(0.04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA.

本文言語English
ページ(範囲)2390-2396
ページ数7
ジャーナルNippon rinsho. Japanese journal of clinical medicine
60
12
出版ステータスPublished - 2002 12
外部発表はい

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「Etanercept」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル